Immunology’s team
The “Immunology” team aims to identify new regulatory functions of hematopoietic cytokines using the extent of their side effects described when used as therapeutic agents. The clinical impact of this research could lead to the identification of new biomarkers and allow a better management of the therapeutic strategy. The objective is to reduce the risk of misuse of cytokines while improving their effectiveness through individualized patient selection.
Our research program aims to study the side effects associated with the clinical use of recombinant erythropoietin (EPO). We have developed the first complete functional EPO-Knock out (KO) available in an adult mouse model by vaccination with a recombinant adenovirus encoding a heterologous EPO form. This model allows us to decipher the extra-erythroid functions of EPO, with a focus on the hematopoietic system.
Our research program over the past three years has allowed us to identify mechanisms regulating platelet heterogeneity that may have an important impact in the prevention and treatment of atherothrombosis. We have demonstrated that EPO is the main regulatory factor for the production of large platelets, uncovering a missing piece of the complex puzzle associated with the pathogenicity of atherothrombosis.
These results could have a significant impact on a better understanding of cardiovascular risk and its therapeutic management. We will now focus on identifying a signature associated with the activation of this specific pathway that could be useful for future clinical trials.
À lire aussi
CNRS honors Néovacs and UTCBS, united for a therapeutic RNA vaccine against asthma
Suresnes, August 29, 2024 - 8am CET - Neovacs (Euronext Growth Paris : ALNEV), a preclinical-stage biopharmaceutical company developing novel therapies for inflammatory and autoimmune diseases, is honored to be listed among the latest CNRS publications following the...
Publication in Advanced Science of Preclinical tests obtained with a pFAR plasmid
Gene Electrotransfer via Conductivity-Clamped Electric Field Focusing Pivots Sensori-Motor DNA Therapeutics: “A Spoonful of Sugar Helps the Medicine Go Down” https://doi.org/10.1002/advs.202401392
Khair Alareth, Caroline Roques and Nasir Arafath with Nathalie Mignet to present UTCBS’s work at the Controlled release society international congress in Bologna.
UTCBS presents its work at the international congress of the "controlled release society" in Bologna. The UTCBS team has shown the interest of nanoparticles both for the imaging of ROS in vivo and the promotion of antioxydant therapeutic activity. Caroline Roques...
The Alnylam Pharmaceuticals 2024 “Interfering RNA & Rare Diseases” Prize has been awarded to Virginie Escriou,
The Alnylam Pharmaceuticals 2024 “Interfering RNA & Rare Diseases” Prize has been awarded to Virginie Escriou,